Iloperidone

TargetMol
Product Code: TAR-T1539
Supplier: TargetMol
CodeSizePrice
TAR-T1539-5mg5mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1539-1mL1 mL * 10 mM (in DMSO)£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1539-10mg10mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1539-25mg25mg£147.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1539-50mg50mg£205.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1539-100mg100mg£318.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1539-200mg200mg£461.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1539-500mg500mg£709.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Iloperidone is an atypical antipsychotic agent that is used for treatment of schizophrenia.
CAS:
133454-47-4
Formula:
C24H27FN2O4
Molecular Weight:
426.488
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.9996
SMILES:
COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O
Target:
Dopamine Receptor; 5-HT Receptor; Adrenergic Receptor

References

1. Kalkman HO, et al. Neuropsychopharmacology, 2001, 25(6), 904-914. 2. Kongsamut S, et al. Eur J Pharmacol, 1996, 317(2-3), 417-423. 3. Szczepanik AM, et al. J Pharmacol Exp Ther, 1996, 278(2), 913-920. 4. Barr AM, et al. Neuropharmacology, 2006, 51(3), 457-465. 5. Ichikawa J, et al. Brain Res, 2002, 956(2), 349-357. 6. Danek P J, W?jcikowski J, Daniel W A. Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy[J]. Toxicology and Applied Pharmacology. 2020, 406: 115239.